Anixa Biosciences, Inc (ANIX)

Etorro trading 970x250
Anixa Biosciences, Inc (ANIX) Logo

About Anixa Biosciences, Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118

Anixa Biosciences, Inc News and around…

Latest news about Anixa Biosciences, Inc (ANIX) common stock and company :

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology
06 Oct, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the China National Intellectual Property Administration (CNIPA) has issued a Notification of Grant of Patent Right on Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
01 Oct, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium
14 Sep, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021. Dr. Conejo-Garcia will discuss a number

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
07 Sep, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer. Dr. Garzone will oversee Anixa's vaccine and therapeutic development programs and will report to the CEO.

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
31 Aug, 2021 Yahoo! Finance

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer
30 Aug, 2021 FinancialContent

TheFDA has signed offAnixa Biosciences Inc's(NASDAQ: ANIX) application for its CAR-T (Chimeric Antigen ...

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
30 Aug, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center (Moffitt).

First Week of April 2022 Options Trading For Anixa Biosciences (ANIX)
26 Aug, 2021 FinancialContent

Investors in Anixa Biosciences Inc (ANIX) saw new options begin trading this week, for the April 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta Variant
25 Aug, 2021 FinancialContent

Anixa Biosciences Inc(NASDAQ: ANIX) has announced that a genomic variant analysis indicates that itspotential compounds ...

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant
25 Aug, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.

Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative
23 Aug, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Director, Dr. Arnold Baskies has been appointed to the World Health Organization's (WHO) Global Breast Cancer Initiative.

Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology
18 Aug, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee. A European patent covering this technology was issued earlier this year.

12 Health Care Stocks Moving In Friday's Pre-Market Session
13 Aug, 2021 FinancialContent

Gainers Biolase (NASDAQ:BIOL) stock moved upwards by 42.49% to $0.9 during Friday's pre-market session. The ...

3 Penny Stocks Insiders Are Buying
28 Jul, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Friday 7/16 Insider Buying Report: ANIX, MGYR
16 Jul, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
12 Jun, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
27 May, 2021 FinancialContent

Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The ...

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
26 May, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI). Anixa Biosciences holds an exclusive worldwide license from Cleveland Clinic for this vaccine technology.

12 Health Care Stocks Moving In Monday's Pre-Market Session
24 May, 2021 FinancialContent

Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market ...

Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application
20 May, 2021 Yahoo! Finance

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Cancer Center.

77 Biggest Movers From Yesterday
14 May, 2021 FinancialContent

Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped ...

OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
07 May, 2021 Yahoo! Finance

OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development.

Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
21 Apr, 2021 Yahoo! Finance

The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.

55 Biggest Movers From Yesterday
20 Apr, 2021 FinancialContent

Gainers Marlin Business Services Corp. (NASDAQ: MRLN) shares surged 50.7% to close at $21.46 on Monday after the company enters ...

Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher
19 Apr, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded down 0.41% to 34,060.60 while the NASDAQ fell 1.08% to 13,900.17. The S&P also ...

Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program
19 Apr, 2021 FinancialContent

Anixa Biosciences Inc(NASDAQ:ANIX) shares drop after theFDA has requested additional informationon its ...

Mid-Day Market Update: Marlin Business Services Rises Following Acquisition News; Anixa Biosciences Shares Plummet
19 Apr, 2021 FinancialContent

Midway through trading Monday, the Dow traded down 0.53% to 34,017.99. while the NASDAQ fell 0.94% to 13,920.74. The S&P also fell, ...

42 Stocks Moving In Monday's Mid-Day Session
19 Apr, 2021 FinancialContent

Gainers Marlin Business Services Corp. (NASDAQ: MRLN) shares jumped 52.6% to $21.73 after the company enters into a definitive ...

Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Views
19 Apr, 2021 FinancialContent

Following the market opening Monday, the Dow traded down 0.27% to 34,107.40 while the NASDAQ fell 0.72% to 13,950.87. The S&P also ...

Anixa Biosciences, Inc (ANIX) is a NASDAQ Common Stock listed in , ,

970x250